LY 2623091

Drug Profile

LY 2623091

Alternative Names: LY-2623091

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Class
  • Mechanism of Action Mineralocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Essential hypertension; Renal failure

Most Recent Events

  • 01 Apr 2015 Eli Lilly completes a phase I pharmacokinetics study in Healthy volunteers in USA (NCT02300259)
  • 01 Mar 2015 Eli Lilly completes a phase II trial in Essential hypertension in Canada, Puerto Rico and USA (NCT02194465)
  • 01 Nov 2014 Eli Lilly initiates enrolment in a phase I pharmacokinetics study in Healthy volunteers in USA (NCT02300259)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top